key: cord-1047374-sbmj9qv2
authors: Cafardi, John; Haas, Douglas; Lamarre, Thomas; Feinberg, Judith
title: Opportunistic Fungal Infection Associated with COVID-19
date: 2021-01-18
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab016
sha: 2d337def7a79ec3ff9f5ce73d6ac58796a12aad2
doc_id: 1047374
cord_uid: sbmj9qv2

We report two cases of severe COVID-19 requiring prolonged hospitalization complicated by the late onset of opportunistic fungal infections, Histoplasmosis and Cryptococcosis.

A c c e p t e d M a n u s c r i p t 3 Invasive fungal infection (IFI) has been increasingly recognized as a severe, late sequel of COVID-19. Invasive pulmonary aspergillosis (IPA) is a well-known complication of severe influenza, with rates in patients with post-influenza pneumonia approaching those seen in patients with myeloid neoplasms, graft versus host disease and lung transplants 1, 2 . While pathogenesis remains under investigation, prolonged critical illness, immune dysregulation, mechanical ventilation and glucocorticoid therapy have been posited as risk factors [3] [4] [5] . We report here two cases of pulmonary mycoses as a late complication of severe COVID-19 with associated cytokine and lymphocyte subset profiles in two patients without pre-existing immune compromising conditions on admission.

A 78-year-old man with a history of hypertension and chronic obstructive pulmonary disease maintained on umeclidinium/vilanterol without home oxygen requirement was admitted with 5 days of myalgia, dyspnea, fever, diarrhea and headache. On presentation he was hypoxic with an oxygen saturation of 88% on ambient air and rapidly developed an increased oxygen requirement. He was admitted to the intensive care unit where he was placed on BIPAP. A nasopharyngeal swab for SARS-CoV-2 nucleic acid was positive and treatment with remdesivir, 200 mg IV once then 100 mg daily for 4 days, and methylprednisolone, 40 mg IV every 12 hours, were administered. He was enrolled in a randomized, blinded, placebo-controlled study of DAS181 (1:1 inhaled recombinant sialidase vs placebo -NCT03808922) and received study medication for 10 days, on hospital days 2 through 12. Following database lock, subject allocation was unblinded and receipt of active drug was confirmed.

The patient remained critically ill for 16 days with a gradual decrease in oxygen requirement, transitioning sequentially from BIPAP to high-flow nasal cannula to standard nasal cannula, and was then transferred to the medical step-down unit. After 4 days he developed recrudescent fever with rapidly progressive respiratory insufficiency, requiring intubation and mechanical ventilation. Bronchoscopy with bronchoalveolar lavage, performed 36 hours after readmission to the intensive care unit, showed growth of Cryptococcus neoformans while serum cryptococcal antigen was not detected. Due to clinical instability and the absence of focal neurologic findings, a lumbar puncture was not obtained. Testing for HIV infection via 4 th generation Ab/Ag assay performed prior to admission was negative. Treatment with liposomal amphotericin B 3 mg/kg for six days was changed to isavuconazole following development of acute kidney injury requiring continuous renal replacement therapy.

The patient continued to deteriorate with an increasing oxygen requirement and hypotension requiring vasopressors. He developed ventilator-associated pneumonia due to multidrug-resistant Enterobacter cloacae and Alcaligenes spp requiring treatment with ceftazidime/avibactam. Despite maximal medical therapy he had continued clinical progression. Care was withdrawn at the family's request and he expired on hospital day 39. A 62-year-old woman with a history of diet-controlled diabetes mellitus, gastroesophageal reflux disease and asthma was admitted with three days of dyspnea, nausea, emesis and diarrhea. Prior to admission she had received oral treatment with levofloxacin and azithromycin without improvement. Chest radiograph at presentation showed extensive bilateral ground glass opacities with oxygen saturation on ambient air of 83%.

SARS-CoV-2 nucleic acid testing of the nasopharynx was positive and treatment with remdesivir, 200 mg IV once then 100 mg IV daily for 4 days, and dexamethasone, 6 mg IV daily, were started. She had a rapid increase in oxygen requirement and was transferred to the intensive care unit where CT angiography of the chest demonstrated occlusion of the right pulmonary artery. Therapeutic anticoagulation with enoxaparin as well as inhaled nitric oxide, tocilizumab (8 mg/kg) and prone positioning were initiated.

Over the next two weeks she had ongoing daily fever between 102 o F and 104 o F. Multiple cultures of blood and urine were negative while lower respiratory tract cultures obtained via bronchoscopy showed growth of Candida spp. Her fever persisted despite empiric therapy with vancomycin and cefepime. On hospital day 26 serum cryptococcal antigen and urinary Histoplasma antigen (MiraVista Diagnostics, Indianapolis, IN) were not detected. However, Histoplasma capsulatum complement fixation titers were positive at > 1:64 (yeast phase) and 1:16 (mycelial phase) and Mband was detected by immunodiffusion (Quest Diagnostics, San Juan Capistrano, CA). After receipt of these results on hospital day 33 treatment with liposomal amphotericin B 3 mg/kg per day was initiated. After 13 days of liposomal amphotericin, therapy was changed to intravenous isavuconazole. She was subsequently discharged and transferred to the inpatient rehabilitation service on hospital day 89, after which she was discharged and has slowly returned to baseline functional status.

These two cases are examples of pulmonary mycoses developing as late sequelae of severe COVID-19 among 195 COVID-19 patients who admitted to the intensive care unit during this time. While invasive pulmonary aspergillosis has been widely recognized as a late complication 6 , the cases of cryptococcosis and histoplasmosis reported with COVID-19 thus far have been associated with either pre-existing infection or coincident immunocompromising disease [7] [8] [9] [10] [11] [12] . Of interest, neither patient had evidence of extrapulmonary disease. M a n u s c r i p t 5 Both patients presented in June/July 2020 and had a number of potential risks for systemic fungal infection, including prolonged mechanical ventilation, lymphopenia, high dose glucocorticoid therapy, broad-spectrum antibiotics, tocilizumab (Patient 2), and immune dysregulation associated with critical illness. While host-pathogen interactions and immune dysregulation play a key role in the pathogenesis of COVID-19, the precise interactions remain incompletely understood at this time [13] [14] [15] [16] . Lymphocyte subset populations via flow cytometry and cytokine profiles (quantitative multiplex bead platform, ARUP Laboratories, Salt Lake City, UT) were obtained during the course of these patient's hospitalizations and are provided in an appendix a for further reference. Data for patient #1 is listed in appendix table #1 while data for patient #2 is listed in appendix table #2.

Both patients received isavuconazole rather than fluconazole and itraconazole, respectively, as recommended by IDSA guidelines. Isavuconazole has in vitro activity against both organisms and demonstrated effectiveness in cases of invasive fungal infection due to Cryptococcus and Histoplasma 17 .

Although Patient 1 was enrolled in a blinded clinical trial of an inhaled recombinant sialidase (DAS181) inhibitor, the proposed mechanism seems unlikely to have influenced the development of pulmonary cryptococcosis. DAS181 is a recombinant fusion protein with a sialidase catalytic domain and a respiratory epithelium anchoring domain; the sialidase domain is capable of transiently cleaving (2,3)-and (2,6)-linked sialic acid receptors 18 . As Cryptococcus does not utilize sialic acid in the process of binding or endocytosis 19 and no cases of pulmonary cryptococcosis have been reported in the use of DAS181 in over 900 subjects to date, the use of DAS181 appears unlikely to be a contributing factor although a relationship cannot be excluded.

Given our experience we believe that, in the proper clinical context, clinicians should consider pulmonary fungal infections such as Cryptococcus or Histoplasmosis in progressive or recrudescent respiratory failure in patients with severe COVID-19.

Dr. Cafardi reports grant funding and advisory board compensation from Gilead Sciences and serves as an investigator for Ansun Biopharma. Dr. Feinberg reports grant funding from Gilead Sciences and advisory board compensation from Gilead Sciences and ViiV Healthcare. There are no other potential conflicts of interest to report. Patient Consent Statement:

Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment

High Rates of Influenza-Associated Invasive Pulmonary Aspergillosis May Not Be Universal: A Retrospective Cohort Study from Alberta

Influenza-Associated Pulmonary Aspergillosis: A Local or Global Lethal Combination?

Influenza-Associated Aspergillosis in Critically Ill Patients

COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment

Aspergillosis Complicating Severe Coronavirus Disease

Hospital-acquired SARS-CoV-2 pneumonia in a person living with HIV

Disseminated Cryptococcosis in a Patient With Metastatic Prostate Cancer Who Died in the Coronavirus Disease 2019 (COVID-19) Outbreak

Detected SARS-CoV-2 in Ascitic Fluid Followed by Cryptococcemia: a Case Report

Coronavirus Disease 2019 (COVID-19) in a Patient with Disseminated Histoplasmosis and HIV-A Case Report from Argentina and Literature Review

COVID-19 associated with AIDS-related disseminated histoplasmosis: a case report

COVID-19-Associated Histoplasmosis in an AIDS Patient

A dynamic COVID-19 immune signature includes associations with poor prognosis

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses

The use of sialidase therapy for respiratory viral infections

M a n u s c r i p t 6 The authors concluded that this report does not include information requiring informed consent for publication. This was reviewed with the chairman of the institutional review board, who agreed with this conclusion.A c c e p t e d M a n u s c r i p t